Coronary restenosis after drug-eluting stent implantation in diabetic patients

Korean Circulation Journal

Volumn 36, Issue 1, 2006, Pages 1-7

  Lim, Do Sun ^a  

^a Korea University Ansan Hospital   (South Korea)

Author keywords

Coronary restenosis; Diabetes

Indexed keywords

ACETYLSALICYLIC ACID; CHEMOKINE; COLLAGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELASTIN; FIBRINOGEN RECEPTOR ANTAGONIST; FK 506 BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; S6 KINASE; THIENO[2,3 B]PYRIDINE DERIVATIVE;

ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DRUG ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HUMAN; PATHOPHYSIOLOGY; PREDICTION; RESTENOSIS; REVIEW; RISK FACTOR;

EID: 33644583478     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2006.36.1.1     Document Type: Review

References (64)

1. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999;48:937-42.
2. Waller BF, Palumbo PJ, Lie JT, Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years: analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 1980;69:498-506.
3. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients: The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818-25.
4. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
5. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
6. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993;22:1141-54.
7. Jeon HS, Chae JK, Moon SK, Kim WH, Ko JK. Early and midterm results of coronary stenting in the diabetic patient. Korean Circ J 1999;29:292-7.
8. Mick MJ, Piedmonte MR, Arnold AM, Simpfendorfer C. Risk stratification for long-term outcome after elective coronary angioplasty: a multivariate analysis of 5,000 patients. J Am Coll Cardiol 1994;24:74-80.
9. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979-89.
10. Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004;109:476-80.
11. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.
12. Kim W, Jeong MH, Kim KH, et al. Long-term clinical and angiographic results of coronary stenting in diabetic patients. Korean Circ J 2001;31:24-30.
13. Schofer J, Schluter M, Rau T, Hammer F, Haag N, Mathey DG. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol 2000;35:1554-9.
14. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
15. Seung KB. Drug eluting stent and percutaneous coronary intervention. Korean Circ J 2003;33:857-60.
16. Kim KH, Jeong MH, Hong SN, et al. The clinical effects of drug-eluting stents for the treatment of coronary in-stent restenosis. Korean Circ J 2005;35:443-7.
17. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
18. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
19. Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-9.
20. Scheen AJ, Warzee F. Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. Diabetes Care 2004;27:1840-1.
21. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002;105:2974-80.
22. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528-35.
23. Kereiakes DJ, Young JJ. Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents. Rev Cardiovasc Med 2005;6 (Suppl 1):S48-58.
24. Piatti P, Monti LD. Insulin resistance, hyperleptinemia and endothelial dysfunction in coronary restenosis. Curr Opin Pharmacol 2005;5:160-4.
25. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-30.
26. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998;98:224-33.
27. Ott I, Neumann FJ, Kenngott S, Gawaz M, Schomig A. Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction. Am J Cardiol 1998;82:938-42.
28. Southgate KM, Fisher M, Banning AP, et al. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res 1996;79:1177-87.
29. Dollery CM, Humphries SE, McClelland A, Latchman DS, McEwan JR. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 1999;99:3199-205.
30. Bauters C, de Groote P, Adamantidis M, et al. Proto-oncogene expression in rabbit aorta after wall injury: first marker of the cellular process leading to restenosis after angioplasty? Eur Heart J 1992;13:556-9.
31. Amant C, Bauters C, Bodart JC, et al. D allele of the angiotensin 1-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997;96:56-60.
32. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serial intravascular ultrasound study. Circulation 1997;95:1366-9.
33. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105:311-20.
34. Takagi T, Yoshida K, Akasaka T, et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: a serial intravascular ultrasound study. J Am Coll Cardiol 2000;36:731-8.
35. Babalik E, Gurmen T, Orhan L, et al. Increased secretion of insulin during oral glucose tolerance test can be a predictor of stent restenosis in nondiabetic patients. Catheter Cardiovasc Interv 2003;58:306-12.
36. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
37. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001;88:954-60.
38. le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001;24:588-97.
39. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
40. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995;95:1869-76.
41. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412-7.
42. Carter AJ. TOR of the cell cycle: are there important implications for diabetics in the era of the drug-eluting stent? Catheter Cardiovasc Interv 2004;61:233-6.
43. Curfman GD. Sirolimus-eluting coronary stents. N Engl J Med 2002;346:1770-1.
44. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70.
45. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999;100:1872-8.
46. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
47. Colombo A, Orlic D, Stankovic G, et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 2003;107:2178-80.
48. Mercado N, Boersma E, Wijns W, et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 2001;38:645-52.
49. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875-80.
50. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol 1999;83:1617-22.
51. Bauters C, Hubert E, Prat A, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998;31:1291-8.
52. West NE, Ruygrok PN, Disco CM, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004;109:867-73.
53. Mazeika P, Prasad N, Bui S, Seidelin PH. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 2003;145:1013-21.
54. Kobayashi Y, de Gregorio J, Kobayashi N, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999;34:651-9.
55. Lau KW, Ding ZP, Johan A, Lim YL. Midterm angiographic outcome of single-vessel intracoronary stent placement in diabetic versus nondiabetic patients: a matched comparative study. Am Heart J 1998;136:150-5.
56. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
57. Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004;27:2654-60.
58. Corpus RA, George PB, House JA, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004;43:8-14.
59. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serial intravascular ultrasound study. Circulation 1997;95:1366-9.
60. Moon KW, Lee JM, Chang K, et al. Oral everolimus reduces adventitial cell activation and neointima formation in balloon-injured rat carotid artery. Korean Circ J 2004;34:983-91.
61. Cha KS, Jeong MH, Lee SU, et al. The effects of local delivery of paclitaxel nanoparticle on porcine coronary stent restenosis. Korean Circ J 2000;30:208-20.
62. Cho MC, Kwak NJ, Piao H, et al. Effect of paclitaxel local delivery on neointimal formation after endothelial denudation of the rat carotid artery. Korean Circ J 2000;30:198-207.
63. Chang KY, Seung KB, Kang DH, et al. The inhibition of neointimal hyperplasia by combination of external radiation and paclitaxel in a rat carotid injury model. Korean Circ J 2000;30:758-66.
64. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247-9.